menu search

Xencor to present preclinical data from novel xmab® cd28 bispecific antibody programs at the american association for cancer research annual meeting 2023

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokin...

March 14, 2023, 4:31 pm

Silence therapeutics: breaking the silence on an under-the-radar mid-stage sirna platform

Silence Therapeutics is an underfollowed British siRNA company focusing on cardiovascular and autoimmune...

March 13, 2023, 11:58 pm

This biopharma stock jumped over 250% on monday: what happened?

Shares of Provention Bio Inc (NASDAQ: PRVB) more than tripled on Monday after Sanofi S.A. (EPA: SAN) confirmed plans of buying the biopharmaceutical c...

March 13, 2023, 8:22 pm

Provention bio shares soar after sanofi agrees to buy company in $2.9b cash deal

French drugmaker Sanofi has announced an agreement to acquire US-based biopharmaceutical company Provention Bio Inc (NASDAQ:PRVB), which focuses on <...

March 13, 2023, 10:15 am

Sanofi to buy provention bio in deal worth $2.9 billion

French pharmaceutical group Sanofi said Monday that it will buy Provention Bio, Inc., a U.S.-based biopharmaceutical company focused on ...

March 13, 2023, 2:49 am

Labcorp (lh) focuses on high-growth areas amid currency woe

In its efforts to expand further, LabCorp (LH) is focusing more on high-growth opportunity areas such as neurodegenerative, ...

March 8, 2023, 12:02 pm

Annexon reports fourth quarter and year-end 2022 financial results and reiterates anticipated milestones

Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023 Oral Small Molecule ANX1502, for ...

March 6, 2023, 11:30 am

Fate therapeutics to present at upcoming march investor conferences

SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage...

March 3, 2023, 9:01 pm

Fate therapeutics to present at upcoming march investor conferences

SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage ...

March 3, 2023, 4:01 pm

Shattuck labs announces participation in upcoming march conferences

AUSTIN, TX and DURHAM, NC, March 01, 2023 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company p...

March 1, 2023, 12:00 pm

Argenx to present at upcoming investor conferences

February 2 7 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of...

February 27, 2023, 1:00 am

Argenx to report full year 2022 financial results and fourth quarter business update on march 2, 2023

February 23 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of ...

February 23, 2023, 1:00 am

Travere: sparsentan approval is likely, but future is uncertain

IgA Nephropathy (IgAN) is a chronic autoimmune disease that affects the kidneys and leads to end-stage ...

February 13, 2023, 5:23 pm

Biondvax presenting at bio ceo & investor conference

JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . ( Nasdaq: BVXV ), a biotechnology company focused on ...

February 2, 2023, 2:15 pm

Trethera announces appointment of r. boyd quinnell to board of directors

LOS ANGELES, Jan. 18, 2023 (GLOBE NEWSWIRE) — Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to develop...

January 18, 2023, 5:37 pm

Fate therapeutics announces termination of collaboration agreement with janssen, pipeline prioritization, next-generation programs, and key 2023 initiatives

Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization...

January 5, 2023, 10:00 pm

Xencor to present at the 41st annual j.p. morgan healthcare conference

MONROVIA, Calif.--( BUSINESS WIRE )--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytok...

January 4, 2023, 4:01 pm

Annexon to present at 41st annual j.p. morgan healthcare conference

BRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...

January 4, 2023, 6:30 am

Argenx to present at 41st annual j.p. morgan healthcare conference

January 3 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of pe...

January 3, 2023, 1:00 am

Genprex boosts its diabetes gene therapy program with the license of additional technology from the university of pittsburgh

Genprex, Inc. (NASDAQ:GNPX) revealed that it has struck an agreement with the University of Pittsburgh for a worldwide, exclusive license to some pat...

December 15, 2022, 9:16 am


Search within

Pages Search Results: